Category: Funding (Page 4 of 4)

Introducing Biolocity: Guiding Medical Innovation to Market

 
The Coulter Translational Fund is excited to announce its next-generation effort, Biolocity.

Biolocity stems from the expansion of a successful five year pilot in which the program awarded over $6.2 million to 40 innovative projects leading to 20 start-ups, and three products on the market. As a result of the Coulter Fund’s successful pilot and the increasing demands for translational funding and mentorship, Biolocity was created to address the need for a broader network of support for university innovators.

“Biolocity extends our successful Coulter Translational Program model to reach a larger, more diverse cohort of innovators at earlier stages of their discovery, guides them using our successful experts-in-residence process, and cultivates individualized links with the commercialization ecosystem,” said Susan Margulies, Chair of the Wallace H. Coulter Department of Biomedical Engineering.  

Similar to the Coulter program, Biolocity provides university innovators with a combination of investment, resources, and guidance that early-stage medical technologies need to reach critical commercialization milestones. We utilize three collaborative methods to advance translational science to the marketplace:

  1. BiolocityU provides educational programming in life science commercialization, trains interns on technology assessment and commercialization strategy, and offers year-round consultations opportunities to faculty innovators.
  2. Biolocity Fund features a bi-annual funding cycle for patient impacting technologies from our partner institutions. Candidates participate in a rigorous application process to identify the most compelling medical technologies to receive funding and coaching.
  3. Biolocity Launch provides awardees with active project management and coordination with the biotech commercialization ecosystem to access resources needed to achieve translational goals.

Biolocity Process Graphic

Bringing both the experience and success of the Coulter process, Biolocity creates a multi-institutional network to support the commercialization of medical technology in the southeast. The program adds new connectivity across Atlanta, while deepening its commitment to Emory University and the Georgia Institute of Technology.

“We are grateful to the Coulter Foundation’s support our pilot and proud of our teams’ successes”, said Shawna Khouri, managing director of Biolocity. “As our program evolves and continues to grow as Biolocity, we look forward to expanding our network with new partners and adding connections within the Atlanta biotech ecosystem.”

To learn more about Biolocity’s upcoming funding cycle and educational opportunities, visit www.biolocity.org.

 

Coulter Translational Program Announces Awards for Innovative Research

Six innovative biomedical research projects awarded

The Coulter Translational Program, in partnership with the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, awarded $765,000 to six biomedical research projects. These awards help bring innovations in patient care into the marketplace.

The Coulter program fund provides annual awards to Emory University and Georgia Institute of Technology research teams who create products with commercial potential that address an unmet clinical need. Funding and project management provided by the Coulter program team is used to bridge the gap in development between early stage university research and its commercialization.

Out of 54 applications in this year’s funding cycle, the below innovative projects were selected by a committee comprised of venture capitalists, industry, entrepreneurs, doctors, biomedical engineers and technology transfer experts from both universities.

  1. Antiviral Peptide: a broad-spectrum antiviral drug used for the treatment of the Influenza virus. The therapeutic discovery platform has identified therapeutic peptides with broad-spectrum antiviral activity. Principal Investigator: Joshy Jacobs, Emory University
  2. Neurodegenerative Disease Diagnostic: a mass spectrometry-based immunoassay that can detect and track biomarkers to determine progression of neurodegenerative disease earlier and more reliably that clinical manifestation of symptoms. Principal Investigators: Allan Levey, Emory University; Duc Duong, Emory University; and Nick Seyfried, Emory University
  3. Nanoparticle Screening for Gene Therapies: a high throughput DNA barcoding platform that identifies lipid nanoparticles that can deliver gene therapies to targeted tissues and organs with high specificity. Principal Investigator: James Dahlman, Georgia Tech
  4. Steerable Guidewire: a robotically steerable guidewire tip to enable greater maneuverability and navigation in vascular spaces. Principal Investigators: Jaydev Desai, Georgia Tech and Zach Bercu, Emory University
  5. TUMAAS Breast Pump: a wearable, portable breast pump that can draw milk with minimal noise. Principal Investigator: Andrea Joyner, Emory University
  6. Wheelchair In-seat Activity Tracker (WiSAT)*: an in-seat activity tracker to encourage weight shifts and reduce pressure ulcer formation. Principal Investigators: Sharon Sonenblum, Georgia Tech, and Stephen Sprigle, Georgia Tech *Support for this project is in partnership with the Rick Hansen Institute.

“There is a rich pipeline of commercializable patient-impacting technologies at Georgia Tech and Emory University. This year’s applicant pool was exceedingly competitive” says Shawna Khouri, managing director of the Coulter Translational Program. “The projects selected to be a part of this cohort have a strong potential for commercialization and we’re eager to work with our PIs to grow these opportunities and advance them aggressively toward the market.”

Page 4 of 4

Powered by WordPress & Theme by Anders Norén